



A Message from Paul Lucas
President & CEO,
GlaxoSmithKline, Canada

At GSK, we are firmly committed to researching, developing and producing the very best medications to help patients in Canada and around the world. We know that access to innovative medicines can not only provide Canadians with a better quality of life, but also reduced health-care costs.

Global competition for R&D investment is fierce. As a leading research-based company, we need to find new ways to work with our partners in academia, government and the private sector to ensure that Canadians reap the benefits of home-grown innovation.

As one of the top 15 corporate investors in Canadian R&D, I am very proud of the leadership role that we have taken in Canada. As highlighted in the accompanying stories, we have recently announced an expansion to our state-of-the-art manufacturing and pharmaceutical development facility to accommodate 22 new global product mandates; we have invested in the MaRS Discovery District; and we have endowed research positions at several prestigious Canadian universities.

GSK will continue to champion Canadian innovation through our commitment to research and development, manufacturing and job creation. The investments outlined in this edition of GSK News represent the type of initiatives that bring with them far-reaching economic and social benefits for Canadians — better health care, knowledge-based jobs and international investment.

GSK Expands Canadian Capabilities

New Product Mandates Bring Manufacturing Expansion

Demonstrating leadership in Canadian research and innovation, GlaxoSmithKline has announced a \$23 million expansion of the company's state-of-the-art manufacturing and pharmaceutical development facility. The increased capacity will add more than 75 jobs to the manufacturing workforce and will allow the company to bring in 22 new global mandates to produce innovative medications.

"At GSK, we are firmly committed to researching, developing and producing the very best medications to help patients," says Paul Lucas, GSK President and CEO. "Here in Canada, we produce a wide range of innovative medicines, and this expansion will allow us to provide more medications for people around the world with diabetes, people living with HIV, and those suffering with depression."

Mr. Lucas made the announcement during a National Biotechnology Week event at GSK's Mississauga, Ontario facilities. Among dignitaries participating in the announcement were Ontario Premier and Minister of Research and Innovation, Dalton McGuinty; Mississauga Mayor, Hazel McCallion; Chair of the Western GTA Convergence Centre, Dr. Ulli Krull; Chair of the MaRS Discovery District, Dr. John Evans; and Ontario Minister of Health and Long-Term Care, George Smitherman.

"We need more companies like GlaxoSmithKline making this kind of commitment to innovation."

Ontario Premier Dalton McGuinty



Ontario Premier Dalton McGuinty tours GlaxoSmithKline's facilities in Mississauga, where GSK President and CEO Paul Lucas (far right) announced a \$23 million manufacturing expansion, job creation and an investment in the MaRS Discovery District in Toronto.

■ continued on reverse



New Research Positions Established in Three Canadian Universities

Three leading Canadian universities have received generous endowments from the *GlaxoSmithKline Pathfinders Fund for Leaders in Canadian Health Science Research*. The fund encourages health science research and fosters medical innovation in Canadian medical schools.

"GSK is dedicated to supporting Canadian research scientists in their exploration and study of diseases," says Dr. John Dillon, GSK Vice-President, Medical Division and Chief Medical Officer. "Through the understanding and discovery of innovative treatments, we can make a real improvement in the quality of life for Canadians and people around the world."



Dr. John Dillon, GSK's Vice-President, Medical Division and Chief Medical Officer with Dr. Chris Mody, Professor and Chief of Division of Respiriology, University of Calgary and Dr. Dennis Salahub, Vice-President, Research and International, University of Calgary announce the creation of the new *GSK Professorship in Inflammatory Lung Disease*.

In Alberta, GSK has provided a \$1 million Pathfinders Fund endowment to both the University of Alberta and the University of Calgary to focus on studies in airway inflammation that will advance scientific understanding of chronic respiratory illness, such as asthma and chronic obstructive pulmonary disease (COPD).

To further the fight against neurological and psychiatric disorders, GSK has also contributed a \$500,000 Pathfinders endowment to help establish the *Dr. J. David Grimes Research Chair* at the University of Ottawa in partnership with the university, the Ottawa Health Research Institute, and the Canadian

Institutes of Health Research. The first chair holder, Dr. Leo Renaud, will focus on research into brain cell function.

By promoting excellence in health science research, the \$22 million Pathfinders Fund is helping Canada to become a leader in research and development. The fund provides opportunities for leading researchers to conduct their important discovery work right here in Canada.

GSK Expands Canadian Capabilities

■ continued from cover

"Global competition for R&D and manufacturing mandates is fierce, and the mandates just awarded to us could have gone to many places around the world," says Mr. Lucas. "But we won them because we're the best at what we do."

The 22 products are in addition to the Canadian company's current mandate to manufacture 75 medicines used to treat many diseases and conditions, including respiratory ailments, gastrointestinal and metabolic disorders and infectious diseases.

In 2004, GSK produced and shipped \$2 billion worth of medications, representing approximately 25 per cent of total pharmaceutical shipments produced in Canada. Currently, 80 per cent of GSK products manufactured in Mississauga are exported, with many going to more than 70 countries around the world.

GSK Supports MaRS Discovery District

GlaxoSmithKline recently announced a multi-year financial commitment to the MaRS Discovery District in Toronto, further enhancing the company's leadership role in Canadian research and development. Located in the heart of Toronto, the MaRS Discovery District brings together best-in-class science, business and academic leaders to accelerate the rate of research and innovation in Canada.

Already a leading research-based company with over \$140 million invested in Canadian R&D in 2004 alone, this investment will bring GSK researchers and corporate staff onto the MaRS campus to support the discovery and commercialization of Canadian innovations.

GSK is proud to take its place among the country's leading scientists, academics and business leaders as they make discoveries that will allow Canadians to do more, feel better and live longer.

GlaxoSmithKline in Canada

GlaxoSmithKline is committed to bringing the power of science to the needs of people to help them do more, feel better and live longer. GSK is a leader in four major therapeutic areas—respiratory ailments, gastrointestinal/metabolic disorders such as diabetes, central nervous system disorders and infectious diseases—as well as vaccines.

GlaxoSmithKline Corporate Communications 905-819-3000